Sensei Biotherapeutics, Inc. (SNSE): Rasio rega marang prakiraan pendapatan
Sensei Biotherapeutics is developing its pipeline by leveraging academic partnerships rather than mergers. This chart, provided by the GURU.Markets platform, shows the forward P/S metric demonstrating price momentum, while the value indicates the most recent figure. Data on SNS-101 and the TMAb platform are driving growth. Simultaneously, Sensei Biotherapeutics is implementing ESG standards, reducing chemical waste through computer modeling.
Rincian analitis perusahaan senseibio.com (SNSE)
- rega saham lan target rega konsensus:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas Sensei Biotherapeutics|SNSE - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal Sensei Biotherapeutics, Inc.|SNSE - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku SNSE|SNSE - Utang jangka dawa|Utang jangka cendhak perusahaan Sensei Biotherapeutics|Rasio cepet senseibio.com
- data bathi bisnis lan rasio investasi:
SNSE - Bathi resik|Bathi sing dikarepake Sensei Biotherapeutics|SNSE - Kapitalisasi marang bathi resik|Prakiraan rega marang bathi Sensei Biotherapeutics, Inc.|SNSE - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan SNSE|SNSE - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Sensei Biotherapeutics|SNSE - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan senseibio.com|SNSE - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Sensei Biotherapeutics
- rincian pendapatan lan dodolan:
Ringkesan analisis perusahaan:Sensei Bio SNSE
Forward P/S measures market expectations for future revenue, allowing for the valuation of a business relative to projected sales and the identification of trend reversal points. By analyzing forward P/S based on forecasts, an investor can see the stability of Sensei Biotherapeutics (SNSE), whose cancer vaccine developments are shielded from geopolitical risks and trade wars, confirming the long-term consensus regarding patent security.
Analisis pesaing
ImmunityBio - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Immunocore Holdings IMCR|JANX - Rasio rega marang prakiraan pendapatan|RCUS (Arcus Corp) - Kapitalisasi marang prakiraan pendapatan|Zymeworks Inc. (ZYME) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep tangotx.com (TNGX)|Multiplikator forward rega marang pendapatan IOVA|IMTX - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan XNCR (Xencor Corp)|Rasio rega marang pendapatan sing dikarepake CMPX|Multiplikator Forward P/S REPL (Replimune Group, Inc.)|Rega forward marang dodolan LYEL|Innate Pharma - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pyxis Oncology, Inc.|cgen.com (CGEN) - Rasio rega marang prakiraan pendapatan|IO Biotech Inc. - Rega forward marang dodolan|STRO (Sutro Biopharma, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S minktherapeutics.com|Rasio rega marang prakiraan pendapatan Werewolf Therapeutics (HOWL)|IMMX: Rega mangsa ngarep marang pendapatan|ALX Oncology Holdings - Multiplikator forward rega marang pendapatan|cuebiopharma.com (CUE) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|PDSB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Sonnet BioTherapeutics SONN|MAIA: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Liminatus Pharma Inc. (LIMN)|Rasio rega marang prakiraan pendapatan LAVA Therapeutics NV|Kapitalisasi marang prakiraan pendapatan NXTC (NextCure Corporation)|Rasio rega marang prakiraan pendapatan Leap Therapeutics, Inc. (LPTX)|Rasio kapitalisasi marang dodolan sing dikarepake intensitytherapeutics.com|Multiplikator Forward P/S TOVX (Theriva Biologics)|Gritstone bio Inc. (GRTS) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Kineta Bio - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake NexImmune Corporation NEXI|TSBX (turnstonebio.com) - Multiplikator forward rega marang pendapatan|vaccinex.com - Rega forward marang dodolan|HARP (Harpoon Therapeutics, Inc.) - Multiplikator Forward P/S
